caption stringlengths 0 3.92k | molecule stringlengths 1 914 | properties listlengths 1 113 | additional_data dict |
|---|---|---|---|
The molecule is a energy source, energy storage, fat storage, thyroxine treatment that impacts atherosclerosis and cardiovascular disease. The molecule is a nutrient that impacts both cancer and pancreatitis. The molecule is a membrane stabilizer and a inflammatory, impacting both obesity and metabolic syndrome. | CCCCCCCCCCCCCCCCCCCCCC(=O)OC[C@@H](COC(=O)CCCCCCCCCCC(C)C)OC(=O)CCCCCCCCCCCC | [
"Energy source",
"Energy storage",
"Atherosclerosis",
"Cardiovascular disease",
"Fat storage",
"Thyroxine treatment",
"Cancer",
"nutrient",
"Pancreatitis",
"Membrane stabilizer",
"Obesity",
"inflammatory",
"Metabolic syndrome"
] | {
"Actives": null,
"Approval Date": null,
"Brand Name": null,
"Indication": null,
"PubChem CIDs": null
} |
The molecule is a environmental contaminant, anti mutagenic, and musty that impacts both shock and pain. The molecule is a food and nutrition and pesticide, belonging to the allelochemic class of molecules, and it impacts both cresol poisoning ibs and abdominal pain. The molecule is a human xenobiotic metabolite, a ant... | O=C1N[C@@H](Cc2cnc[nH]2)C(=O)N2CCCC[C@@H]12 | [
"anti mutagenic",
"musty",
"Shock",
"environmental contaminant",
"Pain",
"Cresol poisoning ibs",
"Abdominal pain",
"allelochemic",
"Food and nutrition",
"pesticide",
"human xenobiotic metabolite",
"rodenticide",
"anti septic",
"Vomiting",
"Hazardous air pollutant",
"Air pollutant",
"... | {
"Actives": null,
"Approval Date": null,
"Brand Name": null,
"Indication": null,
"PubChem CIDs": null
} |
The molecule is a apoptosis that impacts tangier disease, diabetic heart disease, barth syndrome, and non-alcoholic fatty liver disease. The molecule is a stabilizing mitochondrial structure, cholesterol translocation, proton trap for oxidative phosphorylation, stabilizing cytochrome oxidase that impacts aging. | CC/C=C\C/C=C\C/C=C\C/C=C\CCCCC(=O)O[C@H](COC(=O)CCCCCCC/C=C\C/C=C\CCCCC)COP(=O)(O)OC[C@H](O)COP(=O)(O)OC[C@@H](COC(=O)CCCCCCCCC/C=C\C/C=C\CCCCC)OC(=O)CCCCCCCCC/C=C\C/C=C\CCCCC | [
"Tangier disease",
"Apoptosis",
"Diabetic heart disease",
"Barth syndrome",
"Non-alcoholic fatty liver disease",
"Stabilizing mitochondrial structure",
"Cholesterol translocation",
"Proton trap for oxidative phosphorylation",
"Aging",
"Stabilizing cytochrome oxidase"
] | {
"Actives": null,
"Approval Date": null,
"Brand Name": null,
"Indication": null,
"PubChem CIDs": null
} |
The molecule is a stabilizing mitochondrial structure and a proton trap for oxidative phosphorylation that impacts tangier disease, barth syndrome, and diabetic heart disease. The molecule is a cholesterol translocation, stabilizing cytochrome oxidase, apoptosis that impacts aging and non-alcoholic fatty liver disease. | CCCCCC/C=C\C=C/CCCCCCCC(=O)O[C@H](COC(=O)CCCCCCCCCCCC(C)C)COP(=O)(O)OC[C@H](O)COP(=O)(O)OC[C@@H](COC(=O)CCCCCCCCCCCCCCCCCCCCC)OC(=O)CCCCCCCCCCCCCCCCCCCCC | [
"Tangier disease",
"Barth syndrome",
"Stabilizing mitochondrial structure",
"Proton trap for oxidative phosphorylation",
"Diabetic heart disease",
"Aging",
"Cholesterol translocation",
"Non-alcoholic fatty liver disease",
"Stabilizing cytochrome oxidase",
"Apoptosis"
] | {
"Actives": null,
"Approval Date": null,
"Brand Name": null,
"Indication": null,
"PubChem CIDs": null
} |
The molecule is a cholesterol translocation, stabilizing cytochrome oxidase, apoptosis that impacts diabetic heart disease and non-alcoholic fatty liver disease. The molecule is a proton trap for oxidative phosphorylation and a stabilizing mitochondrial structure that impacts aging, tangier disease, and barth syndrome. | CCCCCCCCCCCCCCCCCCCC(=O)O[C@H](COC(=O)CCCCCCCCCCCC(C)C)COP(=O)(O)OC[C@@H](O)COP(=O)(O)OC[C@@H](COC(=O)CCCCCCC)OC(=O)CCCCCCCCCCC(C)CC | [
"Diabetic heart disease",
"Non-alcoholic fatty liver disease",
"Cholesterol translocation",
"Stabilizing cytochrome oxidase",
"Apoptosis",
"Aging",
"Tangier disease",
"Proton trap for oxidative phosphorylation",
"Stabilizing mitochondrial structure",
"Barth syndrome"
] | {
"Actives": null,
"Approval Date": null,
"Brand Name": null,
"Indication": null,
"PubChem CIDs": null
} |
The molecule is a ion channel inhibitor and is pain treatment. | CC(O)=C(C(=N)c1c(F)cccc1Cl)C(=O)N1CCC(c2ccc(S(=O)(=O)Nc3nccs3)cc2)CC1 | [
"ion channel inhibitor",
"pain treatment"
] | {
"Actives": null,
"Approval Date": null,
"Brand Name": null,
"Indication": null,
"PubChem CIDs": null
} |
The molecule is a viral replication inhibitor and belongs to both the anti retroviral and anti hiv classes of molecules. | COC(=O)C(O)c1cc2ccccc2cc1OCc1ccccc1 | [
"anti retroviral",
"viral replication inhibitor",
"anti hiv"
] | {
"Actives": null,
"Approval Date": null,
"Brand Name": null,
"Indication": null,
"PubChem CIDs": null
} |
The molecule is a proton trap for oxidative phosphorylation, stabilizing cytochrome oxidase, stabilizing mitochondrial structure that impacts non-alcoholic fatty liver disease and aging. The molecule is a apoptosis and a cholesterol translocation that impacts tangier disease, diabetic heart disease, and barth syndrome. | CCCCCCCCCCCCCCCCCCCCCC(=O)O[C@H](COC(=O)CCCCCCCCCCCCCCCCCCCC)COP(=O)(O)OC[C@@H](O)COP(=O)(O)OC[C@@H](COC(=O)CCCCCCCCCCCCC)OC(=O)CCCCCCCCCCCCC(C)CC | [
"Non-alcoholic fatty liver disease",
"Proton trap for oxidative phosphorylation",
"Stabilizing cytochrome oxidase",
"Stabilizing mitochondrial structure",
"Aging",
"Tangier disease",
"Diabetic heart disease",
"Apoptosis",
"Cholesterol translocation",
"Barth syndrome"
] | {
"Actives": null,
"Approval Date": null,
"Brand Name": null,
"Indication": null,
"PubChem CIDs": null
} |
It belongs to the gpr40 agonist class of molecules. | CCS(=O)(=O)N1CC(COc2cc(C)c(Br)c(C)c2)C1 | [
"gpr40 agonist"
] | {
"Actives": null,
"Approval Date": null,
"Brand Name": null,
"Indication": null,
"PubChem CIDs": null
} |
The molecule is a stabilizing cytochrome oxidase, cholesterol translocation, stabilizing mitochondrial structure that impacts barth syndrome and aging. The molecule is a proton trap for oxidative phosphorylation and a apoptosis that impacts diabetic heart disease, tangier disease, and non-alcoholic fatty liver disease. | CCCCCCCCCCCCCCCCCCCCCCC(=O)O[C@H](COC(=O)CCCCCCCCCCCC(C)C)COP(=O)(O)OC[C@@H](O)COP(=O)(O)OC[C@@H](COC(=O)CCCCCCCCCCC)OC(=O)CCCCCCCCCCCC | [
"Stabilizing cytochrome oxidase",
"Cholesterol translocation",
"Stabilizing mitochondrial structure",
"Barth syndrome",
"Aging",
"Diabetic heart disease",
"Tangier disease",
"Proton trap for oxidative phosphorylation",
"Non-alcoholic fatty liver disease",
"Apoptosis"
] | {
"Actives": null,
"Approval Date": null,
"Brand Name": null,
"Indication": null,
"PubChem CIDs": null
} |
The molecule is a apoptosis, proton trap for oxidative phosphorylation, cholesterol translocation that impacts tangier disease and barth syndrome. The molecule is a stabilizing mitochondrial structure and a stabilizing cytochrome oxidase that impacts non-alcoholic fatty liver disease, aging, and diabetic heart disease. | CCCCCCCCCCCCCCCCCCCCCC(=O)O[C@H](COC(=O)CCCCCCCCCCCCCCCCC(C)C)COP(=O)(O)OC[C@@H](O)COP(=O)(O)OC[C@@H](COC(=O)CCCCCCCCC(C)C)OC(=O)CCCCCCCCCCCCC(C)C | [
"Apoptosis",
"Tangier disease",
"Proton trap for oxidative phosphorylation",
"Cholesterol translocation",
"Barth syndrome",
"Non-alcoholic fatty liver disease",
"Stabilizing mitochondrial structure",
"Stabilizing cytochrome oxidase",
"Aging",
"Diabetic heart disease"
] | {
"Actives": null,
"Approval Date": null,
"Brand Name": null,
"Indication": null,
"PubChem CIDs": null
} |
The molecule is a flavoring agent, warm, herbal, pharmaceutical, tobacco. | CC/C=C/CCCC/C=C/CCCCCCCC(=O)O | [
"warm",
"Flavoring agent",
"herbal",
"Pharmaceutical",
"tobacco"
] | {
"Actives": null,
"Approval Date": null,
"Brand Name": null,
"Indication": null,
"PubChem CIDs": null
} |
The molecule is a nutrient, energy source, membrane stabilizer that impacts obesity, metabolic syndrome, and pancreatitis. The molecule is a thyroxine treatment and energy storage, and it impacts cardiovascular disease. The molecule is a fat storage and a inflammatory, impacting both atherosclerosis and cancer. | CCCCCCCCCCCCCCCCCCC(=O)OC[C@@H](COC(=O)CCCCCCCCCCCCCCCCCCCCC(C)CC)OC(=O)CCCCCCCCCCC(C)CC | [
"Obesity",
"Metabolic syndrome",
"nutrient",
"Pancreatitis",
"Energy source",
"Membrane stabilizer",
"Thyroxine treatment",
"Cardiovascular disease",
"Energy storage",
"Atherosclerosis",
"Fat storage",
"Cancer",
"inflammatory"
] | {
"Actives": null,
"Approval Date": null,
"Brand Name": null,
"Indication": null,
"PubChem CIDs": null
} |
The molecule is a proton trap for oxidative phosphorylation, apoptosis, cholesterol translocation that impacts barth syndrome and diabetic heart disease. The molecule is a stabilizing cytochrome oxidase and a stabilizing mitochondrial structure that impacts non-alcoholic fatty liver disease, tangier disease, and aging. | CCCCCCCCCCCCCCCCCCCCCCCC(=O)O[C@H](COC(=O)CCCCCCCCCCCCCCCCCC(C)C)COP(=O)(O)OC[C@@H](O)COP(=O)(O)OC[C@@H](COC(=O)CCCCCCCCCC)OC(=O)CCCCCCCCCCCCCCCCCCCC | [
"Barth syndrome",
"Proton trap for oxidative phosphorylation",
"Diabetic heart disease",
"Apoptosis",
"Cholesterol translocation",
"Non-alcoholic fatty liver disease",
"Stabilizing cytochrome oxidase",
"Tangier disease",
"Stabilizing mitochondrial structure",
"Aging"
] | {
"Actives": null,
"Approval Date": null,
"Brand Name": null,
"Indication": null,
"PubChem CIDs": null
} |
The molecule is both a hiv protease inhibitor and a orexin receptor antagonist. | CCNCCc1noc(-c2ccc(F)cn2)n1 | [
"hiv protease inhibitor",
"orexin receptor antagonist"
] | {
"Actives": null,
"Approval Date": null,
"Brand Name": null,
"Indication": null,
"PubChem CIDs": null
} |
The molecule is a pi3k inhibitor and belongs to the cancer treatment class of molecules. | CN(C)C1CCN(Cc2cc3nc(-c4n[nH]c5ccccc45)nc(N4CCOCC4)c3s2)CC1 | [
"cancer treatment",
"pi3k inhibitor"
] | {
"Actives": null,
"Approval Date": null,
"Brand Name": null,
"Indication": null,
"PubChem CIDs": null
} |
The molecule is a apoptosis, proton trap for oxidative phosphorylation, cholesterol translocation that impacts non-alcoholic fatty liver disease and aging. The molecule is a stabilizing cytochrome oxidase and a stabilizing mitochondrial structure that impacts barth syndrome, diabetic heart disease, and tangier disease. | CCCCCCCCCCCCCCCCCCCCCC(=O)O[C@H](COC(=O)CCCCCCCCCCCC(C)C)COP(=O)(O)OC[C@@H](O)COP(=O)(O)OC[C@@H](COC(=O)CCCCCCCCCC)OC(=O)CCCCCCCCCCC | [
"Apoptosis",
"Non-alcoholic fatty liver disease",
"Proton trap for oxidative phosphorylation",
"Cholesterol translocation",
"Aging",
"Barth syndrome",
"Stabilizing cytochrome oxidase",
"Stabilizing mitochondrial structure",
"Diabetic heart disease",
"Tangier disease"
] | {
"Actives": null,
"Approval Date": null,
"Brand Name": null,
"Indication": null,
"PubChem CIDs": null
} |
The molecule is a fat storage that impacts both metabolic syndrome and cardiovascular disease. The molecule is a nutrient and a thyroxine treatment, impacting both atherosclerosis and pancreatitis. | CC/C=C\C/C=C\C/C=C\C/C=C\C/C=C\CCCCCC(=O)OC[C@H](COC(=O)CCCCCCCCCCCCC/C=C\CCCCCCCC)OC(=O)CCCCCC/C=C\C/C=C\C/C=C\CCCCC | [
"Metabolic syndrome",
"Fat storage",
"Cardiovascular disease",
"Atherosclerosis",
"Pancreatitis",
"nutrient",
"Thyroxine treatment"
] | {
"Actives": null,
"Approval Date": null,
"Brand Name": null,
"Indication": null,
"PubChem CIDs": null
} |
The molecule is a nutrient, fat storage, membrane stabilizer that impacts metabolic syndrome, pancreatitis, and cardiovascular disease. The molecule is a energy source that impacts both atherosclerosis and cancer. The molecule is a energy storage and a inflammatory, impacting both obesity and thyroxine treatment. | CCCCCCCCCCCC(=O)O[C@@H](COC(=O)CCCCCCCCCCCCC(C)CC)COC(=O)CCCCCCCCC(C)C | [
"nutrient",
"Metabolic syndrome",
"Fat storage",
"Membrane stabilizer",
"Pancreatitis",
"Cardiovascular disease",
"Atherosclerosis",
"Cancer",
"Energy source",
"Obesity",
"Energy storage",
"Thyroxine treatment",
"inflammatory"
] | {
"Actives": null,
"Approval Date": null,
"Brand Name": null,
"Indication": null,
"PubChem CIDs": null
} |
The molecule is a chk1 inhibitor. | COc1cc(CC2CCN(C(=O)O)CC2)ccc1-c1cc(N)n[nH]1 | [
"chk1 inhibitor"
] | {
"Actives": null,
"Approval Date": null,
"Brand Name": null,
"Indication": null,
"PubChem CIDs": null
} |
The molecule is a inflammatory, fat storage, membrane stabilizer, nutrient that impacts metabolic syndrome and pancreatitis. The molecule is a energy storage and thyroxine treatment, and it impacts cancer. The molecule is a energy source that impacts obesity, cardiovascular disease, and atherosclerosis. | CCC(C)CCCCCCCCCCCCCCCCC(=O)OC[C@H](COC(=O)CCCCCCCCCC(C)C)OC(=O)CCCCCCCCCCCCCCCCCCC(C)C | [
"inflammatory",
"Fat storage",
"Membrane stabilizer",
"Metabolic syndrome",
"nutrient",
"Pancreatitis",
"Energy storage",
"Thyroxine treatment",
"Cancer",
"Obesity",
"Energy source",
"Cardiovascular disease",
"Atherosclerosis"
] | {
"Actives": null,
"Approval Date": null,
"Brand Name": null,
"Indication": null,
"PubChem CIDs": null
} |
The molecule is a stabilizing cytochrome oxidase and a apoptosis that impacts diabetic heart disease, aging, and non-alcoholic fatty liver disease. The molecule is a cholesterol translocation, proton trap for oxidative phosphorylation, stabilizing mitochondrial structure that impacts barth syndrome and tangier disease. | CC/C=C\C/C=C\C/C=C\C/C=C\C/C=C\CCCC(=O)O[C@H](COC(=O)CCCCCCCCC/C=C\C/C=C\CCCCC)COP(=O)(O)OC[C@@H](O)COP(=O)(O)OC[C@@H](COC(=O)CCCCCCCCC/C=C\C/C=C\CCCCC)OC(=O)CCCCCCC/C=C\C/C=C\CCCCC | [
"Diabetic heart disease",
"Stabilizing cytochrome oxidase",
"Apoptosis",
"Aging",
"Non-alcoholic fatty liver disease",
"Barth syndrome",
"Tangier disease",
"Cholesterol translocation",
"Proton trap for oxidative phosphorylation",
"Stabilizing mitochondrial structure"
] | {
"Actives": null,
"Approval Date": null,
"Brand Name": null,
"Indication": null,
"PubChem CIDs": null
} |
The molecule is a fat storage and belongs to the thyroxine treatment class of molecules, impacting metabolic syndrome. The molecule is a nutrient that impacts atherosclerosis, cardiovascular disease, and pancreatitis. | CCCCCCCC/C=C\CCCCCCCCCCCCCC(=O)O[C@H](COC(=O)CCCCCCCCCCC/C=C\CCCCCCCC)COC(=O)CCCCCCCCCCCCCCCCCCCCCCC | [
"Fat storage",
"Metabolic syndrome",
"Thyroxine treatment",
"Atherosclerosis",
"nutrient",
"Cardiovascular disease",
"Pancreatitis"
] | {
"Actives": null,
"Approval Date": null,
"Brand Name": null,
"Indication": null,
"PubChem CIDs": null
} |
It impacts pain treatment. | CC1C2Cc3ccc(O)cc3C1(CCNCc1ccco1)CCN2CC1CC1 | [
"pain treatment"
] | {
"Actives": null,
"Approval Date": null,
"Brand Name": null,
"Indication": null,
"PubChem CIDs": null
} |
The molecule is a emulsifier, a energy source, herbal, fruit, and fruity. The molecule is a energy storage, nutrient, membrane stabilizer, surfactant, herb, and earthy. | CC1=CC[C@@]23[C@@H]([C@@H]12)[C@H](C(C)C)CC[C@H]3C | [
"herbal",
"Emulsifier",
"Energy source",
"fruit",
"fruity",
"Energy storage",
"nutrient",
"Membrane stabilizer",
"herb",
"earthy",
"surfactant"
] | {
"Actives": null,
"Approval Date": null,
"Brand Name": null,
"Indication": null,
"PubChem CIDs": null
} |
The molecule is a fat storage that impacts both thyroxine treatment and cardiovascular disease. The molecule is a nutrient that impacts metabolic syndrome, atherosclerosis, and pancreatitis. | CCCC/C=C\CCCCCCCC(=O)OC[C@@H](COC(=O)CCCCCCCCCCCCC/C=C\CCCCCCCC)OC(=O)CCCCCCCCCCCCC/C=C\CCCCCCCC | [
"Fat storage",
"Thyroxine treatment",
"Cardiovascular disease",
"Metabolic syndrome",
"Atherosclerosis",
"nutrient",
"Pancreatitis"
] | {
"Actives": null,
"Approval Date": null,
"Brand Name": null,
"Indication": null,
"PubChem CIDs": null
} |
The molecule is both a hiv integrase inhibitor and a hiv treatment. | COc1nc2c(cc1NCc1ccccc1C(F)(F)F)c(=O)c(C(=O)O)cn2C(CO)C(C)C | [
"hiv integrase inhibitor",
"hiv treatment"
] | {
"Actives": null,
"Approval Date": null,
"Brand Name": null,
"Indication": null,
"PubChem CIDs": null
} |
The molecule is a insectifuge and a hepatotonic, belonging to the pesticide class of molecules, is choleretic, and has a Cool, saline taste. | O=C([O-])C(O)C(O)C(=O)[O-].[K+].[Na+] | [
"choleretic",
"pesticide",
"taste_evaluation",
"insectifuge",
"hepatotonic"
] | {
"Actives": null,
"Approval Date": null,
"Brand Name": null,
"Indication": null,
"PubChem CIDs": null
} |
The molecule is a shp2 inhibitor. | Cc1nc(N2CCC3(CC2)Cc2ccccc2O3)c(CO)nc1Sc1ccnc2c1OCC1(COC1)N2 | [
"shp2 inhibitor"
] | {
"Actives": null,
"Approval Date": null,
"Brand Name": null,
"Indication": null,
"PubChem CIDs": null
} |
The molecule is a proton trap for oxidative phosphorylation and a stabilizing mitochondrial structure that impacts diabetic heart disease, aging, and non-alcoholic fatty liver disease. The molecule is a cholesterol translocation, stabilizing cytochrome oxidase, apoptosis that impacts barth syndrome and tangier disease. | CC/C=C\C/C=C\C/C=C\C/C=C\C/C=C\C/C=C\CCC(=O)OC[C@H](COP(=O)(O)OC[C@@H](O)COP(=O)(O)OC[C@@H](COC(=O)CCCCCCC/C=C\C/C=C\CCCCC)OC(=O)CCCCC/C=C\C/C=C\C/C=C\C/C=C\C/C=C\CC)OC(=O)CCC/C=C\C/C=C\C/C=C\C/C=C\C/C=C\CC | [
"Diabetic heart disease",
"Aging",
"Non-alcoholic fatty liver disease",
"Proton trap for oxidative phosphorylation",
"Stabilizing mitochondrial structure",
"Barth syndrome",
"Cholesterol translocation",
"Tangier disease",
"Stabilizing cytochrome oxidase",
"Apoptosis"
] | {
"Actives": null,
"Approval Date": null,
"Brand Name": null,
"Indication": null,
"PubChem CIDs": null
} |
The molecule is a proton trap for oxidative phosphorylation that impacts barth syndrome, tangier disease, aging, and diabetic heart disease. The molecule is a stabilizing mitochondrial structure, stabilizing cytochrome oxidase, apoptosis, cholesterol translocation that impacts non-alcoholic fatty liver disease. | CCCCCCCCCCCCCCCCCCCC(=O)OC[C@H](COP(=O)(O)OC[C@@H](O)COP(=O)(O)OC[C@@H](COC(=O)CCCCCCCCCCCC)OC(=O)CCCCCCCCCCCCCCCCC)OC(=O)CCCCCCCCCCCCCCCCCCC | [
"Barth syndrome",
"Tangier disease",
"Proton trap for oxidative phosphorylation",
"Aging",
"Diabetic heart disease",
"Stabilizing mitochondrial structure",
"Non-alcoholic fatty liver disease",
"Stabilizing cytochrome oxidase",
"Apoptosis",
"Cholesterol translocation"
] | {
"Actives": null,
"Approval Date": null,
"Brand Name": null,
"Indication": null,
"PubChem CIDs": null
} |
The molecule is a apoptosis and a stabilizing mitochondrial structure that impacts barth syndrome, non-alcoholic fatty liver disease, and tangier disease. The molecule is a cholesterol translocation, stabilizing cytochrome oxidase, proton trap for oxidative phosphorylation that impacts diabetic heart disease and aging. | CCCCCCCCCCCCC(=O)O[C@H](COC(=O)CCCCCCCCCC)COP(=O)(O)OC[C@H](O)COP(=O)(O)OC[C@@H](COC(=O)CCCCCCCCCCC(C)C)OC(=O)CCCCCCCCCCCCC(C)C | [
"Barth syndrome",
"Apoptosis",
"Stabilizing mitochondrial structure",
"Non-alcoholic fatty liver disease",
"Tangier disease",
"Cholesterol translocation",
"Stabilizing cytochrome oxidase",
"Diabetic heart disease",
"Aging",
"Proton trap for oxidative phosphorylation"
] | {
"Actives": null,
"Approval Date": null,
"Brand Name": null,
"Indication": null,
"PubChem CIDs": null
} |
The molecule is a nutrient that impacts non-alcoholic fatty liver disease, parkinson's disease, diabetes mellitus type 2, and alzheimer's disease. | CCCCC/C=C\CC1OC1CCCCCCCC(=O)OC[C@H](COP(=O)(O)OCCN)O/C=C/CCCCCCCC/C=C\CCCCCC | [
"Non-alcoholic fatty liver disease",
"Parkinson's disease",
"Diabetes mellitus type 2",
"nutrient",
"Alzheimer's Disease"
] | {
"Actives": null,
"Approval Date": null,
"Brand Name": null,
"Indication": null,
"PubChem CIDs": null
} |
The molecule is a cholesterol translocation, stabilizing mitochondrial structure, apoptosis that impacts non-alcoholic fatty liver disease and aging. The molecule is a proton trap for oxidative phosphorylation and a stabilizing cytochrome oxidase that impacts tangier disease, diabetic heart disease, and barth syndrome. | CCCCCCCCCCCCCCCCCCCCCCC(=O)O[C@H](COC(=O)CCCCCCCCCCC(C)C)COP(=O)(O)OC[C@@H](O)COP(=O)(O)OC[C@@H](COC(=O)CCCCCCCCCCC)OC(=O)CCCCCCCCCC(C)C | [
"Cholesterol translocation",
"Stabilizing mitochondrial structure",
"Apoptosis",
"Non-alcoholic fatty liver disease",
"Aging",
"Proton trap for oxidative phosphorylation",
"Tangier disease",
"Stabilizing cytochrome oxidase",
"Diabetic heart disease",
"Barth syndrome"
] | {
"Actives": null,
"Approval Date": null,
"Brand Name": null,
"Indication": null,
"PubChem CIDs": null
} |
The molecule is a nutrient. | CCCCC/C=C\C/C=C\C/C=C\CCCCC(=O)O[C@H](COC(=O)CCCCCCCCC/C=C\CCCCCCCC)COP(=O)(O)OC[C@H](N)C(=O)O | [
"nutrient"
] | {
"Actives": null,
"Approval Date": null,
"Brand Name": null,
"Indication": null,
"PubChem CIDs": null
} |
The molecule is a emulsifier, nutritional supplement, signalling molecule, surfactant. The molecule is a membrane stabilizer, energy source, energy storage, food additive, and smooth. | CCCCCCCCCCCCCC=C[C@@H](O)[C@H](CO[C@@H]1O[C@H](CO)[C@@H](O[C@@H]2O[C@H](CO)[C@H](O[C@@H]3O[C@H](CO)[C@H](O)[C@H](O)[C@H]3CC(C)=O)[C@H](O[C@]3(C(=O)O)C[C@H](O)[C@@H](NC(C)=O)C([C@H](O)[C@@H](CO)O[C@]4(C(=O)O)C[C@H](O)[C@@H](NC(C)=O)C([C@H](O)[C@H](O)CO)O4)O3)[C@H]2O)[C@H](O)[C@H]1O)NC(=O)CCCCCCCCCCCCCCCCCCCCCC | [
"Emulsifier",
"Nutritional supplement",
"signalling molecule",
"surfactant",
"Membrane stabilizer",
"Energy source",
"Energy storage",
"food additive",
"Smooth"
] | {
"Actives": null,
"Approval Date": null,
"Brand Name": null,
"Indication": null,
"PubChem CIDs": null
} |
The molecule is a hdac inhibitor, a tyrosine kinase inhibitor, and a anti proliferative. | Cc1nc(Nc2ncc(C(=O)Nc3c(C)cccc3Cl)s2)cc(S(=O)(=O)N2CCN(c3ncc(C(=O)NO)cn3)CC2)n1 | [
"hdac inhibitor",
"tyrosine kinase inhibitor",
"anti proliferative"
] | {
"Actives": null,
"Approval Date": null,
"Brand Name": null,
"Indication": null,
"PubChem CIDs": null
} |
The molecule is a nutritional supplement, a stabilizing mitochondrial structure, and a membrane stabilizer, and it impacts non-alcoholic fatty liver disease. The molecule is a proton trap for oxidative phosphorylation, food additive, cholesterol translocation that impacts diabetic heart disease and aging. The molecule ... | CCC(C)CCCCCCCCCCCCCCCCC(=O)O[C@H](COC(=O)CCCCCCCCC(C)CC)COP(=O)(O)OC[C@H](O)COP(=O)(O)OC[C@@H](COC(=O)CCCCCCCCC(C)C)OC(=O)CCCCCCCCC(C)C | [
"Non-alcoholic fatty liver disease",
"Nutritional supplement",
"Stabilizing mitochondrial structure",
"Membrane stabilizer",
"Proton trap for oxidative phosphorylation",
"Diabetic heart disease",
"food additive",
"Cholesterol translocation",
"Aging",
"Stabilizing cytochrome oxidase",
"Energy sto... | {
"Actives": null,
"Approval Date": null,
"Brand Name": null,
"Indication": null,
"PubChem CIDs": null
} |
The molecule is a energy storage, nutrient, inflammatory that belongs to the thyroxine treatment class of molecules and impacts both pancreatitis and cardiovascular disease. The molecule is a membrane stabilizer that impacts both metabolic syndrome and atherosclerosis. The molecule is a energy source and a fat storage,... | CCCCCCCC(=O)OC[C@H](COC(=O)CCCCCCCCCCCCCCCCCCCCC(C)C)OC(=O)CCCCCCCCC(C)CC | [
"Energy storage",
"nutrient",
"Pancreatitis",
"inflammatory",
"Thyroxine treatment",
"Cardiovascular disease",
"Metabolic syndrome",
"Membrane stabilizer",
"Atherosclerosis",
"Cancer",
"Energy source",
"Obesity",
"Fat storage"
] | {
"Actives": null,
"Approval Date": null,
"Brand Name": null,
"Indication": null,
"PubChem CIDs": null
} |
The molecule is a apoptosis, cholesterol translocation, stabilizing mitochondrial structure that impacts diabetic heart disease and tangier disease. The molecule is a stabilizing cytochrome oxidase and a proton trap for oxidative phosphorylation that impacts aging, non-alcoholic fatty liver disease, and barth syndrome. | CC/C=C\C/C=C\C/C=C\C/C=C\C/C=C\CCCC(=O)OC[C@H](COP(=O)(O)OC[C@@H](O)COP(=O)(O)OC[C@@H](COC(=O)CCCCCCC/C=C\CCCCCCCC)OC(=O)CCCC/C=C\C/C=C\C/C=C\C/C=C\CC)OC(=O)CCCCCCCCCCCCCCCCC | [
"Diabetic heart disease",
"Apoptosis",
"Cholesterol translocation",
"Stabilizing mitochondrial structure",
"Tangier disease",
"Aging",
"Non-alcoholic fatty liver disease",
"Stabilizing cytochrome oxidase",
"Proton trap for oxidative phosphorylation",
"Barth syndrome"
] | {
"Actives": null,
"Approval Date": null,
"Brand Name": null,
"Indication": null,
"PubChem CIDs": null
} |
The molecule is a fat storage and belongs to the thyroxine treatment class of molecules, impacting atherosclerosis. The molecule is a nutrient that impacts metabolic syndrome, cardiovascular disease, and pancreatitis. | CCCCC/C=C\C/C=C\C/C=C\C/C=C\C/C=C\CCC(=O)OC[C@H](COC(=O)CCCCC/C=C\C/C=C\C/C=C\C/C=C\CCCCC)OC(=O)CCC/C=C\C/C=C\C/C=C\C/C=C\CCCCC | [
"Thyroxine treatment",
"Fat storage",
"Atherosclerosis",
"Metabolic syndrome",
"nutrient",
"Cardiovascular disease",
"Pancreatitis"
] | {
"Actives": null,
"Approval Date": null,
"Brand Name": null,
"Indication": null,
"PubChem CIDs": null
} |
The molecule is a proton trap for oxidative phosphorylation and a stabilizing mitochondrial structure that impacts non-alcoholic fatty liver disease, barth syndrome, and aging. The molecule is a apoptosis, stabilizing cytochrome oxidase, cholesterol translocation that impacts tangier disease and diabetic heart disease. | CC/C=C\C/C=C\C/C=C\C/C=C\CCCCC(=O)OC[C@H](COP(=O)(O)OC[C@H](O)COP(=O)(O)OC[C@@H](COC(=O)CCCCCCCCCCCCCCC)OC(=O)CCCCCCCCC/C=C\C/C=C\C/C=C\CC)OC(=O)CCCCCCCCCCCCCCCCC | [
"Proton trap for oxidative phosphorylation",
"Non-alcoholic fatty liver disease",
"Barth syndrome",
"Aging",
"Stabilizing mitochondrial structure",
"Apoptosis",
"Stabilizing cytochrome oxidase",
"Tangier disease",
"Diabetic heart disease",
"Cholesterol translocation"
] | {
"Actives": null,
"Approval Date": null,
"Brand Name": null,
"Indication": null,
"PubChem CIDs": null
} |
The molecule is a stabilizing cytochrome oxidase, stabilizing mitochondrial structure, cholesterol translocation that impacts aging and non-alcoholic fatty liver disease. The molecule is a proton trap for oxidative phosphorylation and a apoptosis that impacts tangier disease, diabetic heart disease, and barth syndrome. | CC/C=C\C/C=C\C/C=C\C/C=C\CCCCC(=O)O[C@H](COC(=O)CC/C=C\C/C=C\C/C=C\C/C=C\C/C=C\CCCCC)COP(=O)(O)OC[C@H](O)COP(=O)(O)OC[C@@H](COC(=O)CCCCCCCCC/C=C\C/C=C\C/C=C\CC)OC(=O)CCC/C=C\C/C=C\C/C=C\C/C=C\CCCCC | [
"Stabilizing cytochrome oxidase",
"Aging",
"Non-alcoholic fatty liver disease",
"Stabilizing mitochondrial structure",
"Cholesterol translocation",
"Tangier disease",
"Diabetic heart disease",
"Proton trap for oxidative phosphorylation",
"Apoptosis",
"Barth syndrome"
] | {
"Actives": null,
"Approval Date": null,
"Brand Name": null,
"Indication": null,
"PubChem CIDs": null
} |
The molecule is a fat storage and a membrane stabilizer, which has an effect on cancer and impacts both cardiovascular disease and metabolic syndrome, while being thyroxine treatment. The molecule is a nutrient, a energy storage, and a energy source. The molecule is a inflammatory that impacts pancreatitis, obesity, an... | CCC(C)CCCCCCCCCCCCCCCCCCCCC(=O)OC[C@@H](COC(=O)CCCCCCCCCCCCCCCCC(C)CC)OC(=O)CCCCCCCCCCCCCC(C)C | [
"Thyroxine treatment",
"Cardiovascular disease",
"Cancer",
"Fat storage",
"Metabolic syndrome",
"Membrane stabilizer",
"nutrient",
"Energy storage",
"Energy source",
"Pancreatitis",
"Obesity",
"Atherosclerosis",
"inflammatory"
] | {
"Actives": null,
"Approval Date": null,
"Brand Name": null,
"Indication": null,
"PubChem CIDs": null
} |
The molecule is a energy source and fat storage, affecting cancer, and impacting cardiovascular disease, obesity, and atherosclerosis. The molecule is a member of the thyroxine treatment class and affects both pancreatitis and metabolic syndrome. The molecule is a inflammatory, energy storage, nutrient, membrane stabil... | CCC(C)CCCCCCCCCCCCCCCCCCCCC(=O)OC[C@H](COC(=O)CCCCCCCCCCCC(C)C)OC(=O)CCCCCCCCCCCCCCCCC(C)CC | [
"Cardiovascular disease",
"Obesity",
"Energy source",
"Cancer",
"Atherosclerosis",
"Fat storage",
"Thyroxine treatment",
"Pancreatitis",
"Metabolic syndrome",
"inflammatory",
"Energy storage",
"nutrient",
"Membrane stabilizer"
] | {
"Actives": null,
"Approval Date": null,
"Brand Name": null,
"Indication": null,
"PubChem CIDs": null
} |
The molecule is a thyroxine treatment and nutrient, and it impacts atherosclerosis. The molecule is a fat storage that impacts pancreatitis, metabolic syndrome, and cardiovascular disease. | CC/C=C\C/C=C\C/C=C\C/C=C\C/C=C\C/C=C\CCC(=O)O[C@H](COC(=O)CCC/C=C\C/C=C\C/C=C\C/C=C\CCCCC)COC(=O)CCCCCCCCCCCCC | [
"Thyroxine treatment",
"Atherosclerosis",
"nutrient",
"Pancreatitis",
"Metabolic syndrome",
"Cardiovascular disease",
"Fat storage"
] | {
"Actives": null,
"Approval Date": null,
"Brand Name": null,
"Indication": null,
"PubChem CIDs": null
} |
The molecule is a energy storage, emulsifier, stabilizing cytochrome oxidase, membrane stabilizer. The molecule is a nutritional supplement and a cholesterol translocation that impacts aging, diabetic heart disease, and non-alcoholic fatty liver disease. The molecule is a proton trap for oxidative phosphorylation and s... | CCC(C)CCCCCCCCC(=O)OC[C@H](COP(=O)(O)OC[C@H](O)COP(=O)(O)OC[C@@H](COC(=O)CCCCCCCCCCCCCCCCCCC(C)C)OC(=O)CCCCCCCCCCCCCCCCCC(C)C)OC(=O)CCCCCCCCCCCCCCC(C)C | [
"Energy storage",
"Emulsifier",
"Stabilizing cytochrome oxidase",
"Membrane stabilizer",
"Aging",
"Diabetic heart disease",
"Nutritional supplement",
"Non-alcoholic fatty liver disease",
"Cholesterol translocation",
"Tangier disease",
"Smooth",
"Barth syndrome",
"Proton trap for oxidative ph... | {
"Actives": null,
"Approval Date": null,
"Brand Name": null,
"Indication": null,
"PubChem CIDs": null
} |
The molecule is both a hdac inhibitor and a cdk inhibitor. | Cc1nc(-c2ccnc(Nc3ccc(C(=O)NO)cc3)c2)c(C(C)C)[nH]1 | [
"hdac inhibitor",
"cdk inhibitor"
] | {
"Actives": null,
"Approval Date": null,
"Brand Name": null,
"Indication": null,
"PubChem CIDs": null
} |
The molecule is a proton trap for oxidative phosphorylation, cholesterol translocation, apoptosis that impacts diabetic heart disease and tangier disease. The molecule is a stabilizing mitochondrial structure and a stabilizing cytochrome oxidase that impacts aging, barth syndrome, and non-alcoholic fatty liver disease. | CCCCCCCCCCCCCCCC(=O)O[C@H](COC(=O)CCCCCCCCCCCCCC)COP(=O)(O)OC[C@@H](O)COP(=O)(O)OC[C@@H](COC(=O)CCCCCCCCC(C)CC)OC(=O)CCCCCCCCCCC(C)C | [
"Diabetic heart disease",
"Proton trap for oxidative phosphorylation",
"Cholesterol translocation",
"Apoptosis",
"Tangier disease",
"Aging",
"Stabilizing mitochondrial structure",
"Barth syndrome",
"Non-alcoholic fatty liver disease",
"Stabilizing cytochrome oxidase"
] | {
"Actives": null,
"Approval Date": null,
"Brand Name": null,
"Indication": null,
"PubChem CIDs": null
} |
The molecule is a proton trap for oxidative phosphorylation and a stabilizing cytochrome oxidase that impacts diabetic heart disease, aging, and barth syndrome. The molecule is a stabilizing mitochondrial structure, apoptosis, cholesterol translocation that impacts non-alcoholic fatty liver disease and tangier disease. | CCCCCCCCCCCCCCCCCCC(=O)O[C@H](COC(=O)CCCCCCCCCCC(C)CC)COP(=O)(O)OC[C@@H](O)COP(=O)(O)OC[C@@H](COC(=O)CCCCCCCCC(C)C)OC(=O)CCCCCCCCCCCC | [
"Diabetic heart disease",
"Proton trap for oxidative phosphorylation",
"Aging",
"Stabilizing cytochrome oxidase",
"Barth syndrome",
"Non-alcoholic fatty liver disease",
"Stabilizing mitochondrial structure",
"Apoptosis",
"Tangier disease",
"Cholesterol translocation"
] | {
"Actives": null,
"Approval Date": null,
"Brand Name": null,
"Indication": null,
"PubChem CIDs": null
} |
The molecule is a stabilizing mitochondrial structure, proton trap for oxidative phosphorylation, apoptosis that impacts aging and diabetic heart disease. The molecule is a stabilizing cytochrome oxidase and a cholesterol translocation that impacts barth syndrome, tangier disease, and non-alcoholic fatty liver disease. | CC/C=C\C/C=C\C/C=C\C/C=C\C/C=C\C/C=C\CCC(=O)O[C@H](COC(=O)CC/C=C\C/C=C\C/C=C\C/C=C\C/C=C\CCCCC)COP(=O)(O)OC[C@H](O)COP(=O)(O)OC[C@@H](COC(=O)CCCCCCCCC/C=C\C/C=C\C/C=C\CC)OC(=O)CCC/C=C\C/C=C\C/C=C\C/C=C\CCCCC | [
"Aging",
"Stabilizing mitochondrial structure",
"Proton trap for oxidative phosphorylation",
"Apoptosis",
"Diabetic heart disease",
"Barth syndrome",
"Tangier disease",
"Stabilizing cytochrome oxidase",
"Cholesterol translocation",
"Non-alcoholic fatty liver disease"
] | {
"Actives": null,
"Approval Date": null,
"Brand Name": null,
"Indication": null,
"PubChem CIDs": null
} |
The molecule is a nutrient that impacts non-alcoholic fatty liver disease, diabetes mellitus type 2, alzheimer's disease, and parkinson's disease. | CCCCC/C=C\C/C=C\C/C=C\CCCCCCC(=O)OC[C@H](COP(=O)(O)OCCN)OC(=O)CCC[C@@H](O)/C=C\C=C\C=C\[C@@H](O)C/C=C\CCCCC | [
"Non-alcoholic fatty liver disease",
"Diabetes mellitus type 2",
"nutrient",
"Alzheimer's Disease",
"Parkinson's disease"
] | {
"Actives": null,
"Approval Date": null,
"Brand Name": null,
"Indication": null,
"PubChem CIDs": null
} |
The molecule is a stabilizing mitochondrial structure, apoptosis, proton trap for oxidative phosphorylation that impacts barth syndrome and aging. The molecule is a cholesterol translocation and a stabilizing cytochrome oxidase that impacts diabetic heart disease, non-alcoholic fatty liver disease, and tangier disease. | CCCCC/C=C\C/C=C\C/C=C\C/C=C\C/C=C\CCC(=O)OC[C@H](COP(=O)(O)OC[C@@H](O)COP(=O)(O)OC[C@@H](COC(=O)CCC/C=C\C/C=C\C/C=C\C/C=C\CCCCC)OC(=O)CCCCCCC/C=C\CCCCCC)OC(=O)CCCCCCCCCCCCCCCCC | [
"Barth syndrome",
"Stabilizing mitochondrial structure",
"Aging",
"Apoptosis",
"Proton trap for oxidative phosphorylation",
"Diabetic heart disease",
"Non-alcoholic fatty liver disease",
"Tangier disease",
"Cholesterol translocation",
"Stabilizing cytochrome oxidase"
] | {
"Actives": null,
"Approval Date": null,
"Brand Name": null,
"Indication": null,
"PubChem CIDs": null
} |
The molecule is a kinase inhibitor. | Nc1ccc(-c2ccc(CC=O)cc2)c(F)n1 | [
"kinase inhibitor"
] | {
"Actives": null,
"Approval Date": null,
"Brand Name": null,
"Indication": null,
"PubChem CIDs": null
} |
The molecule is a nutrient that impacts both atherosclerosis and cardiovascular disease. The molecule is a fat storage and belongs to the thyroxine treatment class of molecules, impacting both metabolic syndrome and pancreatitis. | CC/C=C\C/C=C\C/C=C\CCCCCCCC(=O)OC[C@H](COC(=O)CCC/C=C\C/C=C\C/C=C\CCCCCCCC)OC(=O)CCCCCCC/C=C\C/C=C\CCCCC | [
"Atherosclerosis",
"nutrient",
"Cardiovascular disease",
"Thyroxine treatment",
"Metabolic syndrome",
"Pancreatitis",
"Fat storage"
] | {
"Actives": null,
"Approval Date": null,
"Brand Name": null,
"Indication": null,
"PubChem CIDs": null
} |
The molecule is a hcv inhibitor and is anti viral. | CCC1C2CN(C(=O)C(C(C)(C)C)NC(=O)OC3CCCC3CCCCC(F)(F)c3nc4ccc(OC)cc4nc3O2)C1C(C)=O | [
"hcv inhibitor",
"anti viral"
] | {
"Actives": null,
"Approval Date": null,
"Brand Name": null,
"Indication": null,
"PubChem CIDs": null
} |
The molecule is a cholesterol translocation, proton trap for oxidative phosphorylation, apoptosis that impacts barth syndrome and tangier disease. The molecule is a stabilizing cytochrome oxidase and a stabilizing mitochondrial structure that impacts aging, diabetic heart disease, and non-alcoholic fatty liver disease. | CCCCCC/C=C\C=C/CCCCCCCC(=O)O[C@H](COC(=O)CCCCCCCCCCC(C)C)COP(=O)(O)OC[C@H](O)COP(=O)(O)OC[C@@H](COC(=O)CCCCCCCCCCCCCCCCCC(C)C)OC(=O)CCCCCCCCCCCCCCCCCCCCCC | [
"Barth syndrome",
"Cholesterol translocation",
"Proton trap for oxidative phosphorylation",
"Tangier disease",
"Apoptosis",
"Aging",
"Diabetic heart disease",
"Stabilizing cytochrome oxidase",
"Stabilizing mitochondrial structure",
"Non-alcoholic fatty liver disease"
] | {
"Actives": null,
"Approval Date": null,
"Brand Name": null,
"Indication": null,
"PubChem CIDs": null
} |
The molecule is a stabilizing cytochrome oxidase, cholesterol translocation, proton trap for oxidative phosphorylation, stabilizing mitochondrial structure that impacts non-alcoholic fatty liver disease. The molecule is a apoptosis that impacts diabetic heart disease, aging, barth syndrome, and tangier disease. | CC/C=C\C/C=C\C/C=C\C/C=C\C/C=C\C/C=C\CCC(=O)O[C@H](COC(=O)CCCCCCC/C=C\C/C=C\CCCCC)COP(=O)(O)OC[C@@H](O)COP(=O)(O)OC[C@@H](COC(=O)CCC/C=C\C/C=C\C/C=C\C/C=C\C/C=C\CC)OC(=O)CCCCCCCCCCCCCCCCC | [
"Stabilizing cytochrome oxidase",
"Cholesterol translocation",
"Proton trap for oxidative phosphorylation",
"Non-alcoholic fatty liver disease",
"Stabilizing mitochondrial structure",
"Apoptosis",
"Diabetic heart disease",
"Aging",
"Barth syndrome",
"Tangier disease"
] | {
"Actives": null,
"Approval Date": null,
"Brand Name": null,
"Indication": null,
"PubChem CIDs": null
} |
The molecule is a stabilizing mitochondrial structure, stabilizing cytochrome oxidase, apoptosis that impacts barth syndrome and non-alcoholic fatty liver disease. The molecule is a cholesterol translocation and a proton trap for oxidative phosphorylation that impacts diabetic heart disease, tangier disease, and aging. | CCCCCCCCCCCCCCCCCCCCCCC(=O)O[C@H](COC(=O)CCCCCCCCCCCCCCCCCC(C)C)COP(=O)(O)OC[C@@H](O)COP(=O)(O)OC[C@@H](COC(=O)CCCCCCCCCCCCC)OC(=O)CCCCCCCCCCC(C)C | [
"Barth syndrome",
"Stabilizing mitochondrial structure",
"Non-alcoholic fatty liver disease",
"Stabilizing cytochrome oxidase",
"Apoptosis",
"Diabetic heart disease",
"Tangier disease",
"Aging",
"Cholesterol translocation",
"Proton trap for oxidative phosphorylation"
] | {
"Actives": null,
"Approval Date": null,
"Brand Name": null,
"Indication": null,
"PubChem CIDs": null
} |
The molecule is electroluminescent and organic electroluminescent, and it has an effect on organic electroluminescence. | c1ccc(-n2c3ccccc3c3cc(-c4ccc5c(c4)c4ccccc4n5-c4cccc(-c5cc6c7c(cccc7c5)-c5ccccc5-6)c4)ccc32)cc1 | [
"organic electroluminescence",
"electroluminescent",
"organic electroluminescent"
] | {
"Actives": null,
"Approval Date": null,
"Brand Name": null,
"Indication": null,
"PubChem CIDs": null
} |
The molecule is a apoptosis, proton trap for oxidative phosphorylation, cholesterol translocation that impacts tangier disease and diabetic heart disease. The molecule is a stabilizing mitochondrial structure and a stabilizing cytochrome oxidase that impacts barth syndrome, non-alcoholic fatty liver disease, and aging. | CC/C=C\C/C=C\C/C=C\C/C=C\C/C=C\CCCCCC(=O)OC[C@H](COP(=O)(O)OC[C@@H](O)COP(=O)(O)OC[C@@H](COC(=O)CCCCCCCCCCCCC)OC(=O)CCCCCCCCCCCCCCCCC)OC(=O)CCCCCCCCC/C=C\C/C=C\CCCCC | [
"Apoptosis",
"Tangier disease",
"Proton trap for oxidative phosphorylation",
"Cholesterol translocation",
"Diabetic heart disease",
"Stabilizing mitochondrial structure",
"Barth syndrome",
"Non-alcoholic fatty liver disease",
"Stabilizing cytochrome oxidase",
"Aging"
] | {
"Actives": null,
"Approval Date": null,
"Brand Name": null,
"Indication": null,
"PubChem CIDs": null
} |
The molecule is a cholesterol translocation, apoptosis, stabilizing cytochrome oxidase that impacts barth syndrome and non-alcoholic fatty liver disease. The molecule is a stabilizing mitochondrial structure and a proton trap for oxidative phosphorylation that impacts aging, diabetic heart disease, and tangier disease. | CCCCCCCCCCCCCCCCCCC(=O)O[C@H](COC(=O)CCCCCCCCCCCCCCC(C)C)COP(=O)(O)OC[C@@H](O)COP(=O)(O)OC[C@@H](COC(=O)CCCCCCCCCCC(C)C)OC(=O)CCCCCCCCCCCCCCC | [
"Barth syndrome",
"Non-alcoholic fatty liver disease",
"Cholesterol translocation",
"Apoptosis",
"Stabilizing cytochrome oxidase",
"Aging",
"Stabilizing mitochondrial structure",
"Proton trap for oxidative phosphorylation",
"Diabetic heart disease",
"Tangier disease"
] | {
"Actives": null,
"Approval Date": null,
"Brand Name": null,
"Indication": null,
"PubChem CIDs": null
} |
The molecule is a stabilizing mitochondrial structure, apoptosis, cholesterol translocation that impacts non-alcoholic fatty liver disease and aging. The molecule is a stabilizing cytochrome oxidase and a proton trap for oxidative phosphorylation that impacts diabetic heart disease, tangier disease, and barth syndrome. | CCCCCCCCCCCCCCCCCCCCCC(=O)O[C@H](COC(=O)CCCCCCCCCCCCCCCCC(C)CC)COP(=O)(O)OC[C@@H](O)COP(=O)(O)OC[C@@H](COC(=O)CCCCCCCCCCC)OC(=O)CCCCCCCCCCCCCCCC(C)C | [
"Non-alcoholic fatty liver disease",
"Stabilizing mitochondrial structure",
"Apoptosis",
"Aging",
"Cholesterol translocation",
"Stabilizing cytochrome oxidase",
"Diabetic heart disease",
"Proton trap for oxidative phosphorylation",
"Tangier disease",
"Barth syndrome"
] | {
"Actives": null,
"Approval Date": null,
"Brand Name": null,
"Indication": null,
"PubChem CIDs": null
} |
The molecule is a fat storage that impacts both metabolic syndrome and thyroxine treatment. The molecule is a nutrient that impacts pancreatitis, cardiovascular disease, and atherosclerosis. | CCCCCCCC/C=C\C/C=C\C/C=C\CCCC(=O)OC[C@H](COC(=O)CCCCCCCCCCCCCC)OC(=O)CCCCCCCCCCCCC | [
"Fat storage",
"Metabolic syndrome",
"Thyroxine treatment",
"nutrient",
"Pancreatitis",
"Cardiovascular disease",
"Atherosclerosis"
] | {
"Actives": null,
"Approval Date": null,
"Brand Name": null,
"Indication": null,
"PubChem CIDs": null
} |
The molecule is a nutrient that impacts both metabolic syndrome and thyroxine treatment. The molecule is a fat storage that impacts cardiovascular disease, atherosclerosis, and pancreatitis. | CCCCC/C=C\C/C=C\CCCCCCCCCC(=O)OC[C@H](COC(=O)CCC/C=C\C/C=C\C/C=C\CCCCCCCC)OC(=O)CCCCCCC/C=C\CCCCCCCC | [
"Metabolic syndrome",
"Thyroxine treatment",
"nutrient",
"Cardiovascular disease",
"Fat storage",
"Atherosclerosis",
"Pancreatitis"
] | {
"Actives": null,
"Approval Date": null,
"Brand Name": null,
"Indication": null,
"PubChem CIDs": null
} |
The molecule is a muscarinic receptor antagonist. | COc1cc(NC(=O)CCN2CCC(OC(=O)Nc3ccsc3-c3cccc(F)c3)CC2)c(Cl)cc1CNCC(O)c1ccc(O)c2[nH]c(=O)ccc12 | [
"muscarinic receptor antagonist"
] | {
"Actives": null,
"Approval Date": null,
"Brand Name": null,
"Indication": null,
"PubChem CIDs": null
} |
The molecule is a energy storage, fat storage, energy source that impacts atherosclerosis, pancreatitis, and obesity. The molecule is a inflammatory that impacts both cancer and metabolic syndrome. The molecule is a nutrient, a membrane stabilizer, and a thyroxine treatment, and it impacts cardiovascular disease. | CCCCCCCCCCCCC(=O)O[C@@H](COC(=O)CCCCCCCCCCCCCCCCCC(C)C)COC(=O)CCCCCCCCCCCCCC(C)C | [
"Energy storage",
"Atherosclerosis",
"Fat storage",
"Pancreatitis",
"Energy source",
"Obesity",
"inflammatory",
"Cancer",
"Metabolic syndrome",
"nutrient",
"Membrane stabilizer",
"Cardiovascular disease",
"Thyroxine treatment"
] | {
"Actives": null,
"Approval Date": null,
"Brand Name": null,
"Indication": null,
"PubChem CIDs": null
} |
The molecule is a cholesterol translocation and a proton trap for oxidative phosphorylation that impacts tangier disease, non-alcoholic fatty liver disease, and aging. The molecule is a stabilizing mitochondrial structure, stabilizing cytochrome oxidase, apoptosis that impacts diabetic heart disease and barth syndrome. | CCCCCCCCCCCCC(=O)OC[C@H](COP(=O)(O)OC[C@H](O)COP(=O)(O)OC[C@@H](COC(=O)CCCCCCCCCCCCCCC(C)C)OC(=O)CCCCCCCCCCCCCCCCC(C)C)OC(=O)CCCCCCCCCCC(C)C | [
"Tangier disease",
"Non-alcoholic fatty liver disease",
"Cholesterol translocation",
"Proton trap for oxidative phosphorylation",
"Aging",
"Stabilizing mitochondrial structure",
"Stabilizing cytochrome oxidase",
"Diabetic heart disease",
"Barth syndrome",
"Apoptosis"
] | {
"Actives": null,
"Approval Date": null,
"Brand Name": null,
"Indication": null,
"PubChem CIDs": null
} |
It belongs to both the diabetes treatment and glp1 receptor modulator classes of molecules. | CNC(Cc1ccc(-c2ccc(OC)cc2OC)cc1)C(C)=O | [
"diabetes treatment",
"glp1 receptor modulator"
] | {
"Actives": null,
"Approval Date": null,
"Brand Name": null,
"Indication": null,
"PubChem CIDs": null
} |
The molecule is a apoptosis that impacts aging, barth syndrome, tangier disease, and diabetic heart disease. The molecule is a stabilizing cytochrome oxidase, proton trap for oxidative phosphorylation, stabilizing mitochondrial structure, cholesterol translocation that impacts non-alcoholic fatty liver disease. | CCCCCCCCCCCCCCCCCCCC(=O)OC[C@H](COP(=O)(O)OC[C@@H](O)COP(=O)(O)OC[C@@H](COC(=O)CCCCCCCCC)OC(=O)CCCCCCCCC(C)CC)OC(=O)CCCCCCCCCCCCCCCCCCC(C)C | [
"Apoptosis",
"Aging",
"Barth syndrome",
"Tangier disease",
"Diabetic heart disease",
"Non-alcoholic fatty liver disease",
"Stabilizing cytochrome oxidase",
"Proton trap for oxidative phosphorylation",
"Stabilizing mitochondrial structure",
"Cholesterol translocation"
] | {
"Actives": null,
"Approval Date": null,
"Brand Name": null,
"Indication": null,
"PubChem CIDs": null
} |
It impacts electron transport. | c1ccc(-c2cc(-c3ccccc3)c3nc(-c4cc(-n5c6ccccc6c6ccccc65)c(-c5ccccc5)c(-n5c6ccccc6c6ccccc65)c4)oc3c2)cc1 | [
"electron transport"
] | {
"Actives": null,
"Approval Date": null,
"Brand Name": null,
"Indication": null,
"PubChem CIDs": null
} |
The molecule is a stabilizing mitochondrial structure, apoptosis, stabilizing cytochrome oxidase that impacts aging and barth syndrome. The molecule is a cholesterol translocation and a proton trap for oxidative phosphorylation that impacts non-alcoholic fatty liver disease, tangier disease, and diabetic heart disease. | CC/C=C\C/C=C\C/C=C\C/C=C\C/C=C\C/C=C\CCC(=O)O[C@H](COC(=O)CCC/C=C\C/C=C\C/C=C\C/C=C\CCCCC)COP(=O)(O)OC[C@@H](O)COP(=O)(O)OC[C@@H](COC(=O)CCCCC/C=C\C/C=C\C/C=C\C/C=C\C/C=C\CC)OC(=O)CCCCCCC/C=C\CCCCCC | [
"Aging",
"Stabilizing mitochondrial structure",
"Apoptosis",
"Stabilizing cytochrome oxidase",
"Barth syndrome",
"Non-alcoholic fatty liver disease",
"Tangier disease",
"Cholesterol translocation",
"Proton trap for oxidative phosphorylation",
"Diabetic heart disease"
] | {
"Actives": null,
"Approval Date": null,
"Brand Name": null,
"Indication": null,
"PubChem CIDs": null
} |
The molecule is a sedative and belongs to the anti emetic class, featuring both a Slightly bitter taste and a Odorless. The molecule is a first generation antipsychotic, dopamine uptake inhibitor, non-narcotic analgesic and belongs to the cholinergic antagonist class of molecules. | OC(CCCN1CCCCC1)(c1ccccc1)c1ccccc1 | [
"sedative",
"taste_evaluation",
"Odor_evaluation",
"anti emetic",
"cholinergic antagonist",
"first generation antipsychotic",
"dopamine uptake inhibitor",
"non-narcotic analgesic"
] | {
"Actives": null,
"Approval Date": null,
"Brand Name": null,
"Indication": null,
"PubChem CIDs": null
} |
The molecule is a stabilizing cytochrome oxidase that impacts barth syndrome, tangier disease, aging, and non-alcoholic fatty liver disease. The molecule is a apoptosis, proton trap for oxidative phosphorylation, cholesterol translocation, stabilizing mitochondrial structure that impacts diabetic heart disease. | CCCCCCCCCCCCCCCCC(=O)OC[C@H](COP(=O)(O)OC[C@@H](O)COP(=O)(O)OC[C@@H](COC(=O)CCCCCCCCCC)OC(=O)CCCCCCCCCCCC(C)C)OC(=O)CCCCCCCCCCCCCCCC(C)C | [
"Stabilizing cytochrome oxidase",
"Barth syndrome",
"Tangier disease",
"Aging",
"Non-alcoholic fatty liver disease",
"Apoptosis",
"Proton trap for oxidative phosphorylation",
"Diabetic heart disease",
"Cholesterol translocation",
"Stabilizing mitochondrial structure"
] | {
"Actives": null,
"Approval Date": null,
"Brand Name": null,
"Indication": null,
"PubChem CIDs": null
} |
The molecule is a proton trap for oxidative phosphorylation that impacts barth syndrome, aging, non-alcoholic fatty liver disease, and diabetic heart disease. The molecule is a stabilizing mitochondrial structure, apoptosis, stabilizing cytochrome oxidase, cholesterol translocation that impacts tangier disease. | CC/C=C\C/C=C\C/C=C\C/C=C\C/C=C\C/C=C\CCC(=O)OC[C@H](COP(=O)(O)OC[C@H](O)COP(=O)(O)OC[C@@H](COC(=O)CCCCCCCCC/C=C\C/C=C\C/C=C\CC)OC(=O)CCC/C=C\C/C=C\C/C=C\C/C=C\CCCCC)OC(=O)CCC/C=C\C/C=C\C/C=C\C/C=C\C/C=C\CC | [
"Proton trap for oxidative phosphorylation",
"Barth syndrome",
"Aging",
"Non-alcoholic fatty liver disease",
"Diabetic heart disease",
"Tangier disease",
"Stabilizing mitochondrial structure",
"Apoptosis",
"Stabilizing cytochrome oxidase",
"Cholesterol translocation"
] | {
"Actives": null,
"Approval Date": null,
"Brand Name": null,
"Indication": null,
"PubChem CIDs": null
} |
The molecule is a nutrient. | CC1OC(Oc2c(-c3ccc(O)cc3)oc3cc(OC4OC(CO)C(O)C(O)C4O)cc(O)c3c2=O)C(OC2OC(COC(=O)/C=C/c3ccc(O)cc3)C(O)C(O)C2O)C(O)C1O | [
"nutrient"
] | {
"Actives": null,
"Approval Date": null,
"Brand Name": null,
"Indication": null,
"PubChem CIDs": null
} |
It impacts cancer treatment. | CC(=O)NCc1ccc(CN2CCC(Cc3ccc(-n4c(-c5cc(C(C)C)c(O)cc5O)n[nH]c4=O)cc3)CC2)cc1 | [
"cancer treatment"
] | {
"Actives": null,
"Approval Date": null,
"Brand Name": null,
"Indication": null,
"PubChem CIDs": null
} |
The molecule is a energy source, fat storage, membrane stabilizer, inflammatory that impacts thyroxine treatment and metabolic syndrome. It impacts atherosclerosis, cardiovascular disease, and cancer. The molecule is a energy storage and a nutrient, impacting both pancreatitis and obesity. | CCCCCCCCCCCCCCCCCCCC(=O)O[C@H](COC(=O)CCCCCCCCCCCCCC)COC(=O)CCCCCCCCCCCCCCCCCCCCC(C)CC | [
"Thyroxine treatment",
"Energy source",
"Fat storage",
"Membrane stabilizer",
"Metabolic syndrome",
"inflammatory",
"Atherosclerosis",
"Cardiovascular disease",
"Cancer",
"Energy storage",
"Pancreatitis",
"Obesity",
"nutrient"
] | {
"Actives": null,
"Approval Date": null,
"Brand Name": null,
"Indication": null,
"PubChem CIDs": null
} |
The molecule is a kinase inhibitor. | O=C(c1cc(NCc2ccccc2)nc2ccc(-c3ccc4c(c3)OCO4)cc12)N1CCCC1N1CCCCC1 | [
"kinase inhibitor"
] | {
"Actives": null,
"Approval Date": null,
"Brand Name": null,
"Indication": null,
"PubChem CIDs": null
} |
The molecule is a cholesterol translocation, stabilizing mitochondrial structure, proton trap for oxidative phosphorylation that impacts non-alcoholic fatty liver disease and tangier disease. The molecule is a stabilizing cytochrome oxidase and a apoptosis that impacts diabetic heart disease, barth syndrome, and aging. | CCCCCCCCCCCCCCCCCCCCCC(=O)O[C@H](COC(=O)CCCCCCCCCCCCCCCCCC(C)C)COP(=O)(O)OC[C@@H](O)COP(=O)(O)OC[C@@H](COC(=O)CCCCCCCCCCC)OC(=O)CCCCCCCCCCCCCCCCCC(C)C | [
"Non-alcoholic fatty liver disease",
"Tangier disease",
"Cholesterol translocation",
"Stabilizing mitochondrial structure",
"Proton trap for oxidative phosphorylation",
"Diabetic heart disease",
"Stabilizing cytochrome oxidase",
"Barth syndrome",
"Aging",
"Apoptosis"
] | {
"Actives": null,
"Approval Date": null,
"Brand Name": null,
"Indication": null,
"PubChem CIDs": null
} |
The molecule is a stabilizing cytochrome oxidase, proton trap for oxidative phosphorylation, stabilizing mitochondrial structure that impacts aging and non-alcoholic fatty liver disease. The molecule is a apoptosis and a cholesterol translocation that impacts diabetic heart disease, tangier disease, and barth syndrome. | CC/C=C\C/C=C\C/C=C\C/C=C\C/C=C\C/C=C\CCC(=O)O[C@H](COC(=O)CC/C=C\C/C=C\C/C=C\C/C=C\C/C=C\CCCCC)COP(=O)(O)OC[C@@H](O)COP(=O)(O)OC[C@@H](COC(=O)CCCCCCC/C=C\C/C=C\CCCCC)OC(=O)CCCCCCCCC/C=C\C/C=C\CCCCC | [
"Aging",
"Stabilizing cytochrome oxidase",
"Proton trap for oxidative phosphorylation",
"Non-alcoholic fatty liver disease",
"Stabilizing mitochondrial structure",
"Diabetic heart disease",
"Apoptosis",
"Tangier disease",
"Cholesterol translocation",
"Barth syndrome"
] | {
"Actives": null,
"Approval Date": null,
"Brand Name": null,
"Indication": null,
"PubChem CIDs": null
} |
The molecule is a nutrient. | CCCCCCCCCCCCCC(=O)OC[C@H](COP(=O)(O)OC[C@H](N)C(=O)O)OC(=O)CCC/C=C\C/C=C\C/C=C\C/C=C\CCC[C@H](C)O | [
"nutrient"
] | {
"Actives": null,
"Approval Date": null,
"Brand Name": null,
"Indication": null,
"PubChem CIDs": null
} |
The molecule is a energy source, nutrient, energy storage, fat storage, membrane stabilizer, inflammatory. It has an effect on cancer, impacting both cardiovascular disease and obesity. The molecule is a thyroxine treatment that impacts metabolic syndrome, pancreatitis, and atherosclerosis. | CCC(C)CCCCCCCCCCCCCCCCC(=O)OC[C@H](COC(=O)CCCCCCCCCCCCCCCCC(C)C)OC(=O)CCCCCCCCC(C)CC | [
"Energy source",
"nutrient",
"Energy storage",
"Fat storage",
"Membrane stabilizer",
"inflammatory",
"Cardiovascular disease",
"Cancer",
"Obesity",
"Metabolic syndrome",
"Thyroxine treatment",
"Pancreatitis",
"Atherosclerosis"
] | {
"Actives": null,
"Approval Date": null,
"Brand Name": null,
"Indication": null,
"PubChem CIDs": null
} |
The molecule is a energy source, a emulsifier, and a cholesterol translocation, and it impacts aging. The molecule is a membrane stabilizer, food additive, stabilizing cytochrome oxidase that impacts non-alcoholic fatty liver disease and barth syndrome. The molecule is a energy storage, a surfactant, a stabilizing mito... | CCCCCC/C=C\C=C/CCCCCCCC(=O)OC[C@H](COP(=O)(O)OC[C@@H](O)COP(=O)(O)OC[C@@H](COC(=O)CCCCCCCCCCC(C)C)OC(=O)CCCCCCCCCCC(C)CC)OC(=O)CCCCCCCCCCCCCCCC(C)C | [
"Energy source",
"Emulsifier",
"Aging",
"Cholesterol translocation",
"Membrane stabilizer",
"food additive",
"Non-alcoholic fatty liver disease",
"Stabilizing cytochrome oxidase",
"Barth syndrome",
"Smooth",
"Energy storage",
"surfactant",
"Stabilizing mitochondrial structure",
"Diabetic h... | {
"Actives": null,
"Approval Date": null,
"Brand Name": null,
"Indication": null,
"PubChem CIDs": null
} |
The molecule is a protein kinase inhibitor. | CNCc1ccc(-c2cnc3c(-c4ccccn4)c(N)nn3c2)cc1 | [
"protein kinase inhibitor"
] | {
"Actives": null,
"Approval Date": null,
"Brand Name": null,
"Indication": null,
"PubChem CIDs": null
} |
The molecule is a nutrient that impacts non-alcoholic fatty liver disease, parkinson's disease, alzheimer's disease, and diabetes mellitus type 2. | CCCCC/C=C\C/C=C\C/C=C\C/C=C\CCCCCC(=O)O[C@H](COC(=O)CCC[C@@H](O)/C=C/C=C\C/C=C\C=C\[C@@H](O)CCCCC)COP(=O)(O)OCCN | [
"Non-alcoholic fatty liver disease",
"Parkinson's disease",
"Alzheimer's Disease",
"Diabetes mellitus type 2",
"nutrient"
] | {
"Actives": null,
"Approval Date": null,
"Brand Name": null,
"Indication": null,
"PubChem CIDs": null
} |
The molecule is a stabilizing mitochondrial structure and a cholesterol translocation that impacts aging, non-alcoholic fatty liver disease, and tangier disease. The molecule is a stabilizing cytochrome oxidase, proton trap for oxidative phosphorylation, apoptosis that impacts diabetic heart disease and barth syndrome. | CCCCCCCCCCCCCCCC(=O)O[C@H](COC(=O)CCCCCCCCCC(C)C)COP(=O)(O)OC[C@@H](O)COP(=O)(O)OC[C@@H](COC(=O)CCCCCCCCC(C)CC)OC(=O)CCCCCCCCC(C)CC | [
"Stabilizing mitochondrial structure",
"Cholesterol translocation",
"Aging",
"Non-alcoholic fatty liver disease",
"Tangier disease",
"Stabilizing cytochrome oxidase",
"Proton trap for oxidative phosphorylation",
"Diabetic heart disease",
"Apoptosis",
"Barth syndrome"
] | {
"Actives": null,
"Approval Date": null,
"Brand Name": null,
"Indication": null,
"PubChem CIDs": null
} |
The molecule is a inflammatory and a nutrient, which impacts obesity, pancreatitis, and cancer, and is characterized as thyroxine treatment. The molecule is a energy source that impacts both cardiovascular disease and atherosclerosis. The molecule is a energy storage, a fat storage, and a membrane stabilizer, and it im... | CCC(C)CCCCCCCCCCCCCCCCC(=O)OC[C@@H](COC(=O)CCCCCCCCC(C)C)OC(=O)CCCCCCCCCC(C)C | [
"Obesity",
"Thyroxine treatment",
"inflammatory",
"nutrient",
"Pancreatitis",
"Cancer",
"Energy source",
"Cardiovascular disease",
"Atherosclerosis",
"Energy storage",
"Fat storage",
"Metabolic syndrome",
"Membrane stabilizer"
] | {
"Actives": null,
"Approval Date": null,
"Brand Name": null,
"Indication": null,
"PubChem CIDs": null
} |
The molecule is a nutrient that impacts parkinson's disease, diabetes mellitus type 2, alzheimer's disease, and non-alcoholic fatty liver disease. | CC/C=C\C[C@@H](O)/C=C/C=C/C=C\C=C/[C@H](O)[C@@H](O)CCCC(=O)OC[C@H](COP(=O)(O)OCCN)O/C=C/CCCCCC/C=C\CCCCCCCC | [
"Parkinson's disease",
"Diabetes mellitus type 2",
"Alzheimer's Disease",
"nutrient",
"Non-alcoholic fatty liver disease"
] | {
"Actives": null,
"Approval Date": null,
"Brand Name": null,
"Indication": null,
"PubChem CIDs": null
} |
The molecule is a nutrient that impacts both atherosclerosis and pancreatitis. The molecule is a fat storage and belongs to the thyroxine treatment class of molecules, impacting both cardiovascular disease and metabolic syndrome. | CC/C=C\C/C=C\C/C=C\C/C=C\C/C=C\CCCCCC(=O)OC[C@H](COC(=O)CCCCCCCCCCCCCCCCC)OC(=O)CCCCCCC/C=C\CCCCCCCC | [
"nutrient",
"Atherosclerosis",
"Pancreatitis",
"Thyroxine treatment",
"Fat storage",
"Cardiovascular disease",
"Metabolic syndrome"
] | {
"Actives": null,
"Approval Date": null,
"Brand Name": null,
"Indication": null,
"PubChem CIDs": null
} |
The molecule is a liquid crystal composition, which is part of both the dielectric and liquid crystal classes, and it influences both liquid crystal display and low voltage. | CCCCc1ccc(C(F)(F)Oc2ccc(C(F)(F)Oc3ccc(C#N)c(F)c3)cc2)cc1 | [
"liquid crystal display",
"dielectric",
"liquid crystal composition",
"low voltage",
"liquid crystal"
] | {
"Actives": null,
"Approval Date": null,
"Brand Name": null,
"Indication": null,
"PubChem CIDs": null
} |
The molecule is a stabilizing cytochrome oxidase and a energy storage, impacting both barth syndrome and diabetic heart disease. The molecule is a surfactant, proton trap for oxidative phosphorylation, emulsifier, food additive, membrane stabilizer. The molecule is a energy source that impacts aging, non-alcoholic fatt... | CC(C)CCCCCCCCCCCCCCCCCCC(=O)OC[C@H](COP(=O)(O)OC[C@@H](O)COP(=O)(O)OC[C@@H](COC(=O)CCCCCCCCCC(C)C)OC(=O)CCCCCCCCCCCCCCCCC(C)C)OC(=O)CCCCCCCCCCCCCCCCC(C)C | [
"Stabilizing cytochrome oxidase",
"Barth syndrome",
"Diabetic heart disease",
"Energy storage",
"surfactant",
"Proton trap for oxidative phosphorylation",
"Emulsifier",
"food additive",
"Membrane stabilizer",
"Aging",
"Non-alcoholic fatty liver disease",
"Tangier disease",
"Energy source",
... | {
"Actives": null,
"Approval Date": null,
"Brand Name": null,
"Indication": null,
"PubChem CIDs": null
} |
The molecule is a apoptosis, stabilizing cytochrome oxidase, proton trap for oxidative phosphorylation, cholesterol translocation that impacts tangier disease. The molecule is a stabilizing mitochondrial structure that impacts aging, diabetic heart disease, non-alcoholic fatty liver disease, and barth syndrome. | CC/C=C\C/C=C\C/C=C\C/C=C\C/C=C\C/C=C\CCC(=O)OC[C@H](COP(=O)(O)OC[C@H](O)COP(=O)(O)OC[C@@H](COC(=O)CCC/C=C\C/C=C\C/C=C\C/C=C\C/C=C\CC)OC(=O)CCCCC/C=C\C/C=C\C/C=C\C/C=C\C/C=C\CC)OC(=O)CCCCCCC/C=C\CCCCCC | [
"Apoptosis",
"Stabilizing cytochrome oxidase",
"Tangier disease",
"Proton trap for oxidative phosphorylation",
"Cholesterol translocation",
"Aging",
"Diabetic heart disease",
"Stabilizing mitochondrial structure",
"Non-alcoholic fatty liver disease",
"Barth syndrome"
] | {
"Actives": null,
"Approval Date": null,
"Brand Name": null,
"Indication": null,
"PubChem CIDs": null
} |
The molecule is a saccharomyces cerevisiae metabolite, energy storage, energy source, surfactant, metabotoxin, human metabolite. The molecule is a food and nutrition, a membrane stabilizer, and fruity. The molecule is a acidogen, a emulsifier, a neurotoxin, and pharmaceutical. | C[C@]12CC[C@H]3[C@@H](CCC4=CC(=O)CC[C@@]43C)[C@@H]1CC[C@@H]2C(=O)CO | [
"Saccharomyces cerevisiae metabolite",
"Energy storage",
"Energy source",
"surfactant",
"Metabotoxin",
"human metabolite",
"Food and nutrition",
"fruity",
"Membrane stabilizer",
"Pharmaceutical",
"Acidogen",
"Emulsifier",
"neurotoxin"
] | {
"Actives": null,
"Approval Date": null,
"Brand Name": null,
"Indication": null,
"PubChem CIDs": null
} |
The molecule is a apoptosis, cholesterol translocation, proton trap for oxidative phosphorylation, stabilizing cytochrome oxidase that impacts aging. The molecule is a stabilizing mitochondrial structure that impacts non-alcoholic fatty liver disease, diabetic heart disease, barth syndrome, and tangier disease. | CCCCC/C=C\C/C=C\CCCCCCCC(=O)OC[C@H](COP(=O)(O)OC[C@@H](O)COP(=O)(O)OC[C@@H](COC(=O)CCCCCCCCCCCCCCC)OC(=O)CCCCCCCCCCCCC)OC(=O)CCCCCCC/C=C\C/C=C\CCCCC | [
"Apoptosis",
"Cholesterol translocation",
"Aging",
"Proton trap for oxidative phosphorylation",
"Stabilizing cytochrome oxidase",
"Non-alcoholic fatty liver disease",
"Diabetic heart disease",
"Barth syndrome",
"Tangier disease",
"Stabilizing mitochondrial structure"
] | {
"Actives": null,
"Approval Date": null,
"Brand Name": null,
"Indication": null,
"PubChem CIDs": null
} |
The molecule is a apoptosis and a stabilizing cytochrome oxidase that impacts barth syndrome, aging, and diabetic heart disease. The molecule is a proton trap for oxidative phosphorylation, stabilizing mitochondrial structure, cholesterol translocation that impacts non-alcoholic fatty liver disease and tangier disease. | CCCCCCCCCCCCCC(=O)O[C@H](COC(=O)CCCCCCCCCC)COP(=O)(O)OC[C@H](O)COP(=O)(O)OC[C@@H](COC(=O)CCCCCCCCCCC(C)C)OC(=O)CCCCCCCCCCC(C)CC | [
"Apoptosis",
"Stabilizing cytochrome oxidase",
"Barth syndrome",
"Aging",
"Diabetic heart disease",
"Proton trap for oxidative phosphorylation",
"Stabilizing mitochondrial structure",
"Non-alcoholic fatty liver disease",
"Cholesterol translocation",
"Tangier disease"
] | {
"Actives": null,
"Approval Date": null,
"Brand Name": null,
"Indication": null,
"PubChem CIDs": null
} |
It impacts diabetes mellitus, alzheimer's disease, parkinson's disease, and cardiovascular disease. It has an effect on stomach cancer, and impacts colorectal cancer, seizure, and breast cancer. | CC/C=C\C/C=C\C/C=C\C/C=C\C=C/C(O)C/C=C\CCC(=O)OC[C@H](COP(=O)(O)O[C@@H]1[C@H](O)[C@H](O)[C@@H](O)[C@H](O)[C@H]1O)OC(=O)CCCCCCC/C=C\CCCCCCCC | [
"Diabetes mellitus",
"Alzheimer's Disease",
"Parkinson's disease",
"Cardiovascular disease",
"Stomach cancer",
"Colorectal cancer",
"Seizure",
"Breast cancer"
] | {
"Actives": null,
"Approval Date": null,
"Brand Name": null,
"Indication": null,
"PubChem CIDs": null
} |
The molecule is a proton trap for oxidative phosphorylation, stabilizing cytochrome oxidase, stabilizing mitochondrial structure that impacts diabetic heart disease and tangier disease. The molecule is a cholesterol translocation and a apoptosis that impacts non-alcoholic fatty liver disease, barth syndrome, and aging. | CCCCCCCCCCCCCCCCCCCCCCCC(=O)O[C@H](COC(=O)CCCCCCCCCCCCCCCCCCCCCC)COP(=O)(O)OC[C@@H](O)COP(=O)(O)OC[C@@H](COC(=O)CCCCCCCCCCC(C)CC)OC(=O)CCCCCCCCCCCCCC(C)C | [
"Diabetic heart disease",
"Proton trap for oxidative phosphorylation",
"Stabilizing cytochrome oxidase",
"Stabilizing mitochondrial structure",
"Tangier disease",
"Non-alcoholic fatty liver disease",
"Barth syndrome",
"Aging",
"Cholesterol translocation",
"Apoptosis"
] | {
"Actives": null,
"Approval Date": null,
"Brand Name": null,
"Indication": null,
"PubChem CIDs": null
} |
The molecule is a wnt pathway inhibitor. | c1cc(N2CCCCC2)c2[nH]c(-c3n[nH]c4ccc(-c5cncc(CN6CCCCC6)c5)cc34)nc2n1 | [
"wnt pathway inhibitor"
] | {
"Actives": null,
"Approval Date": null,
"Brand Name": null,
"Indication": null,
"PubChem CIDs": null
} |
The molecule is a anti inflammatory. | CC1CCCC(C)N1c1nnc2ccc(OC3CCC(NC(=O)N(OC=O)c4cc(C(C)(C)C)nn4-c4ccc(Cl)c(CN5CCN(C)CC5)c4)c4ccccc43)cn12 | [
"anti inflammatory"
] | {
"Actives": null,
"Approval Date": null,
"Brand Name": null,
"Indication": null,
"PubChem CIDs": null
} |
Subsets and Splits
No community queries yet
The top public SQL queries from the community will appear here once available.